Tamoxifen’s days as the go-to drug for hormone suppression and prevention of breast cancer recurrence may be fading into history. Researchers now estimate that a class of low-cost, generic aromatase inhibitors reduce breast cancer recurrence rates 30 percent more than does tamoxifen, and reduce the rate of death from breast cancer recurrence 40 percent relative to those not taking any hormone suppression drugs. Researchers also point to the potential of what they call a “one-two punch” that consists of aromatase inhibitors followed by bisphosphonates (typically prescribed for osteoporosis). Read more here. What is hardly mentioned are the sometimes severe side effects caused by both classes of drugs. Have you or anyone you known switched from tamoxifen to an aromatase inhibitor?